Clinical expression of Menkes disease in females with normal karyotype by Møller, Lisbeth Birk et al.
RESEARCH Open Access
Clinical expression of Menkes disease in females
with normal karyotype
Lisbeth Birk Møller
1*, Malgorzata Lenartowicz
2, Marie-Therese Zabot
3, Arnaud Josiane
4, Lydie Burglen
5,
Chris Bennett
6, Daniel Riconda
7, Richard Fisher
8, Sandra Janssens
9, Shehla Mohammed
10, Margreet Ausems
11,
Zeynep Tümer
1, Nina Horn
1 and Thomas G Jensen
12
Abstract
Background: Menkes Disease (MD) is a rare X-linked recessive fatal neurodegenerative disorder caused by
mutations in the ATP7A gene, and most patients are males. Female carriers are mosaics of wild-type and mutant
cells due to the random X inactivation, and they are rarely affected. In the largest cohort of MD patients reported
so far which consists of 517 families we identified 9 neurologically affected carriers with normal karyotypes.
Methods: We investigated at-risk females for mutations in the ATP7A gene by sequencing or by multiplex ligation-
dependent probe amplification (MLPA). We analyzed the X-inactivation pattern in affected female carriers,
unaffected female carriers and non-carrier females as controls, using the human androgen-receptor gene
methylation assay (HUMAR).
Results: The clinical symptoms of affected females are generally milder than those of affected boys with the same
mutations. While a skewed inactivation of the X-chromosome which harbours the mutation was observed in 94%
of 49 investigated unaffected carriers, a more varied pattern was observed in the affected carriers. Of 9 investigated
affected females, preferential silencing of the normal X-chromosome was observed in 4, preferential X-inactivation
of the mutant X chromosome in 2, an even X-inactivation pattern in 1, and an inconclusive pattern in 2. The X-
inactivation pattern correlates with the degree of mental retardation in the affected females. Eighty-one percent of
32 investigated females in the control group had moderately skewed or an even X-inactivation pattern.
Conclusion: The X- inactivation pattern alone cannot be used to predict the phenotypic outcome in female
carriers, as even those with skewed X-inactivation of the X-chromosome harbouring the mutation might have
neurological symptoms.
Background
Menkes Disease (MD [MIM 309400]) is a rare X-linked
recessive disorder, with an incidence of about 1:298.000
[1] and is caused by mutations in the gene ATP7A
[MIM 300011]. This gene encodes a copper transporting
P-type ATPase, essential for the release of dietary cop-
per from the intestine to the body, including the brain.
The clinical features of MD are consequences of an
impaired copper distribution and the malfunction of a
large number of copper-requiring enzymes [2]. Classical
MD is characterized by mental retardation, hypothermia,
seizures, cutis laxa, hypo-pigmentation, abnormal hair
(kinky hair or pili torti), and decreased serum cerulo-
plasmin levels [3].
The majority of Menkes patients are males and, to our
knowledge, only 9 affected females have been described
so far [4-10]. Five of these patients had X-autosomal
translocations [5-7,9,10] one had 45X/46XX mosaicism
[4], one had an unknown karyotype [8], and two
patients had normal karyotypes [4]. Skewed X-inactiva-
tion has been reported previously in unaffected female
carriers [11], but to our knowledge, X-inactivation has
not previously been investigated in females who are
affected with MD, but have a normal karyotype. This
report includes the clinical description and molecular
characterization of 9 affected females with normal
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pattern in the disease-manifesting carriers with the pat-
tern in 49 asymptomatic MD carriers and the pattern in
32 normal females with no ATP7A mutation.
Methods
Subjects
In a cohort of 517 unrelated families referred to the
Kennedy Center in Denmark for genetic confirmation of
MD, we found 10 manifesting carriers. One patient with
45X/46XX mosaicism has been described previously [4]
and will not be described further here. Nine of the
affected carriers, F1-F9, have normal karyotypes. The
females were born in Europe (United Kingdom, France
or Germany) or United States from 1969 to 2002. The
clinical phenotypes of patients F1 and F2 have been
described previously [4,12].
Patient F1 (family, 9529) was born at 32 weeks gesta-
tion. Neonatally, sepsis and hyperbilirubinemia were
suspected because of prematurity and a peculiar face
was noted. At 31/2-4 months old: Ceruloplasmin: 0.14
g/l (normal: 0.15-0.60), S-Copper: 2 μmol/l (normal: 10-
26 μmol/l). She had pneumonia, and was subsequently
hospitalized several times due to other recurrent infec-
tions. She had stiff, coarse and pili torti hair, an enlarged
liver and myoclonic jerks. The EEG was abnormal. At 5
years of age: Her motor development had reached the
level of a 11/2-year-old child. She could only express
single words, but her capacity for understanding lan-
guage was better. A liver biopsy revealed a copper con-
tent in the lowest end of the normal range: 20 μg/g
(normal: 20-45 μg/g), and an intestinal biopsy revealed
an increased copper content: 47 μg/g (normal: 10-20 μg/
g). Increased
64Cu uptake was observed in amniotic cells
(from 16
th week of gestation) and in fibroblasts when
s h ew a s4y e a r so l d :5 2 . 3n g
64Cu/mg protein/20 hours,
(normal: 11.5-26.7 ng). Her brother suffered from classi-
cal MD and died at 6 months of age. Two heterozygous
sisters (F1-S1 and F1-S2), both also born prematurely,
had no symptoms of MD.
Patient F2 (family, 93232) was born at 38 weeks gesta-
tion. Neonatally, no problems were observed. At 11
months: She was hospitalized because of severe muscular
h y p o t o n i aa n df a i l u r et ot h r i v e .S h eh a dm y o c l o n i cs e i -
zures, tremor and ataxia, and suffered from orthostatic
hypotension. The EEG revealed numerous rapid rhyth-
mic waves and small 4- slow bilateral overlapping waves.
Pili torti of the hair was noted at the time of the diagno-
sis, but is no longer present. She had left-sided talipes
and osteoporosis. There were recurrent episodes of infec-
tions, especially otitis during childhood. The skin was dry
and joints loose during infancy and childhood. Deafness
was proved at the age of 2 years. Ceruloplasmin: 0.35 g/l
(normal: 0.15-0.60), S-copper: 978 μg/l (normal: 850 -
1650 μg/l) at 5 years. Increased
64Cu uptake and reten-
tion in fibroblasts: 87.7 ng
64Cu/mg protein/20 hours and
66% retention, (normal: 11.5-26.7 ng uptake and 9.7-
22.7% retention). During childhood and adolescence she
went to a special-needs school, but her mental retarda-
tion remains significant. She is unable to read and write
and does not have any language. She is not able to walk
without aid but can walk a maximum of 50 meters with
the help of a walker and requires assistance to use of a
wheel-chair. Due to a dysmetry of the arms, self-feeding
is difficult. At 34 years of age she lives in a center for dis-
abled people. No copper treatment was given. There is,
to our knowledge, no affected male in this family.
Patient F3 (family, 9228). In the first months of life,
she suffered from frequent diarrhoea and motor devel-
opment delay. MRI (at about 1 year) revealed cerebral
and particularly cerebellar atrophy. She was unable to
h o l dh e rh e a du pa t7m o n t h sa n du n a b l et os i tu pa t
14 months. The hair was sparse with pili torti. Copper
histidine was administered when she was 21 months.
Prior to treatment her psychomotor development was
retarded, and she had significant feeding difficulties with
loss of weight. Following treatment, her psychomotor
function improved and weight was gained rapidly. The
ceruloplasmin level was below normal at 13 months, 1.5
μmol/l (normal: 2-4.30), but it rose to normal after cop-
per treatment. She suffered from amyotrophy and dys-
metria, and had frequent respiratory infections until age
10. She is mentally retarded and attends a special
school. Her development at 9 years corresponded to
that of a 21/2-year-old. She has never been able to walk
independently, but is able to move around on her bot-
tom. At the age of 12 years, she has no language, but
communicates using pictograms. Increased
64Cu uptake
and retention in fibroblasts: 122 ng
64Cu/mg protein/20
hours and 60.2% retention, (normal: 11.5-26.7 ng uptake
and 9.7-22.7% retention). Her maternal uncle suffered
from classical MD and died at the age of 18 months.
Patient F4 (family, 9229). She is only mildly affected.
She has a slightly high arched palate, narrow thorax and
slightly dry skin. The hair is thick dark, not typical of
MD patients. She was able to sit up at 9 months and to
walk at 3 years. She had some problems with language
and mild learning difficulties, for which she was at a
special school. Copper treatment has never been given.
At 11 years of age: Ceruloplasmin: 0.35 g/l (normal: 0.2-
0.4 g/l) and S-Copper: 19 μmol/l (normal: 12-25 μmol/l)
were normal. Increased
64Cu uptake performed on
amniotic cells from 16
th week of gestation, and on fibro-
blasts when she was 22 years old: 40.1 ng
64Cu/mg pro-
tein/20 hours and 38.5% retention, (normal: 11.5-26.7
ng uptake and 9.7-22.7% retention). Her brother suf-
fered from classical MD and died at the age of 8
months.
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months, and to walk without support at 2 years. She
could talk at 3 years, but has significant learning diffi-
culties (IQ 64, 10 years old). Ceruloplasmin: 37.8 mg/dl
(normal: 20-60 mg/dl) S-Copper: 114 μg/dl (normal: 60-
180 mg/dl). The hair was brittle and sparse with pili
torti. Her EEG was abnormal when she was 10 years
old. Her mother has also mild learning difficulties. Her
brother suffered from a slightly milder form of MD and
died at the age of 7 years and 8 months.
Patient F6 (family, 92209). There were no early neona-
tal problems. She was subsequently noted to have short
fine hair, a large fontanelle, and low muscular tone. The
skin is dry and hypopigmented, and she has severe
developmental delay. No copper treatment was given.
Increased
64Cu uptake and retention in fibroblasts: 66.2
ng
64Cu/mg protein/20 hours uptake with 45% retention,
(normal: 11.5-26.7 ng uptake and 9.7-22.7% retention).
Her brother suffered from classical MD and died at 21/
2 years of age.
Patient F7 (family, 92283). She has severe mental and
motor retardation. She had seizures until the age of 4.
At the age of 41 years old she was in residential care.
She is not able to walk. The hair is thin, fragile, and the
skin dry. Her brother suffered from classical MD and
died at 27 months. Slightly increased
64Cu uptake and
retention in fibroblasts: 34 ng
64Cu/mg protein/20 hours
and 30.7% retention, (normal: 11.5-26.7 ng uptake and
9.7-22.7% retention).
Patient F8 (family, 92292). She has blondish-brown
hair that is moderately coarse. At the age of 14 years
she was mildly mentally retarded. In addition, she had
mild hypopigmentation and prominent areas of demar-
cated hypopigmentation all over her body but most pro-
nounced over her abdomen, buttocks and left thigh. The
vessels are tortuous.
64Cu uptake was normal but reten-
tion slightly increased: 22 ng
64Cu/mg protein/20 hours
with 25-43% retention, (normal: 11.5-26.7 ng uptake and
9.7-22.7% retention). Her brother suffered from classical
MD and died 25 months old. The mother and half-sister
(F8-S1) are also carriers of the mutation in the ATP7A
genes and have some signs of MD. The two sisters and
the brother all have different fathers. The mother and
the sister are both neurologically normal, but they both
have some skin hypopigmentation, especially the sister
who has also tortuous vessels, low serum copper and
ceruloplasmin.
Patient F9 (family, 94228). She had mild psychomotor
delay and was at the age of 29 years mildly mentally
h a n d i c a p p e dw i t ha nI Qo f8 3 .A tt h ea g eo f2y e a r s ,
she suffered from convulsions. At the age of 13 she had
skeletal changes (lumbosacral lordosis, genu valgum, flat
feet, arachnodactyly), and ataxia. The
64Cu uptake in
fibroblasts was slightly increased: 28.4 ng
64Cu/mg
protein/20 hours and a clearly increased retention:
33.5% (normal: 11.5-26.7 ng uptake and 9.7-22.7% reten-
tion). No treatment was given. Her brother suffered
from classical MD but received copper treatment and
lived until the age of 71/2 years. At the age of 29 years
she had a “professional capacities certificate” and is
working. Her sister (F9-S1), also a carrier of the muta-
tion, has mild symptoms, with an IQ slightly below
normal.
Investigation of carrier status
The carrier status of the female family members was
determined by testing for the identified family-specific
mutation in ATP7A by either sequencing or multiplex
ligation-dependent probe amplification analysis (MLPA)
(Salsa P104 kit, MRC, Amsterdam, Holland), depending
on the type of mutation.
DNA and RNA isolation and cDNA synthesis
Genomic DNA was prepared from peripheral blood
lymphocytes, Epstein-Barr virus transformed lympho-
cytes, or cultured fibroblasts with the NaCl extraction
method [13]. RNAeasy was used for RNA isolation
(QIAgen, Bothell, WA) and single-stranded cDNA was
synthesized using the High-Capacity cDNA Archive Kit
(Applied Biosystems, Foster, CA).
X-inactivation pattern
The methylation status of the human androgen receptor
(HUMARA) gene was used as an indicator for X-chro-
mosome inactivation [14,15]. The amplified products
were analysed using an ABI 3130XL Genetic Analyzer,
and the ratio between the signal intensities of the two
alleles was calculated using GeneMapper 3.0 software
(Applied Biosystems, Foster, CA). For each female, the
ratio between signals from the two alleles in the undi-
gested sample was used as a correction factor. DNA
from an affected male from the same family was
included whenever possible in order to reveal the allelic
AR variant on the mutant X-chromosome.
Quantitation of ATP7A transcript
Real-time PCR amplification of ATP7A transcripts from
fibroblasts from the patient F2 was carried out on
cDNA with an ABI7300 Genetic Analyzer in accordance
with the manufacturer’si n s t r u c t i o n s( A p p l i e dB i o s y s -
tems, Foster, CA) as described previously [16]. We used
FAM-labelled Taq-Man probes and primers that anneal
to the junction between exon 22/exon 23 and exon 1/
exon 2 in ATP7A, respectively (Applied Biosystems
assay numbers: Hs00921963_m1 and Hs00921966_m1).
A VIC-probe and primers to human GADPH (Applied
Biosystems assay numbers: 4326317E) were used as an
endogenous control.
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Copper uptake and retention in amniotic cells and fibro-
blasts was performed as described previously [17].
Results
The Menkes gene is controlled by X-inactivation
In males, fibroblasts with a mutation in the ATP7A gene
accumulate and retain more
64Cu than normal cells
[17]. Heterozygous females are expected to be mosaic
for ATP7A gene expression with one population of cells
expressing the wild-type ATP7A gene and the other
population expressing the mutated ATP7A gene due to
random X-chromosome inactivation [18]. This has pre-
viously been shown biochemically by isolating two dif-
ferent cell populations (clones) from a pool of
fibroblasts from a heterozygous female; one cell popula-
tion accumulated a large amount of copper, just like
cells from affected males, while the other cell population
behaved like normal control cells [18]. We confirmed
this inactivation pattern by investigating the expressed
allele from two such isolated clones. Using RT-PCR ana-
lysis, we found that the cell clone with the increased
copper uptake expressed mutant ATP7A transcripts,
whereas the cell clone with the normal copper uptake
expressed wild-type transcripts (Figure 1).
Identification of mutations in affected female carriers
ATP7A mutations were identified in all 9 females,
except for F2 (Table 1). The coding exons of ATP7A in
F2 were screened for mutations on genomic DNA, but
no mutations could be identified. In this patient the
ATP7A transcript was below the detection limit, in con-
trast to the normal amount of the endogenous control
GADPH transcript (not shown).
Based on the clinical phenotypes and the carrier status
we suggest that all 9 clinically affected females are suf-
fering from MD (F1-F9). This is supported by the fact
that the copper uptake and/or retention were increased
in all affected females (not measured in patient F5).
Serum copper and ceruloplasmin were not reduced in
all 9 patients, but the levels can be normal - also in
affected males with mild symptoms (Table 1).
X-inactivation patterns in affected female carriers
A possible association between skewed X-inactivation
and disease severity was investigated by measuring the
X-inactivation patterns in the 9 affected females (Table
2). One female (F9) had a highly skewed inactivation of
the mutant X-chromosome (ratio = 100:0), and three
females (F6, F7, and probably F2) had highly skewed
inactivation of the normal X-chromosome (ratio ≤ 4:96).
Two females had moderately skewed inactivation of
either the mutant X-chromosome (F4) (ratio = 80:20) or
the normal X-chromosome (F1) (ratio = 24:76), and one
female had an even X-inactivation pattern (F5). The X-
inactivation assay was inconclusive for two females (F3,
F8) due to homozygosity of the AR polymorphism.
The clinical phenotypes, biochemical and molecular
findings of the 9 clinically affected carriers (F1-F9) are
summarized in Table 1.
X-inactivation patterns of unaffected female carriers
For comparison, the X-inactivation patterns of 49 unaf-
fected female carriers were measured. The first sub-
group was composed of 15 women from the same
families as the manifesting carriers. (Table 2). The sec-
ond sub-group consisted of 34 unaffected carriers from
other Menkes families (Table 3). A very high fraction of
the unaffected carriers (69%, 34 females out of 49) had
highly skewed inactivation of the mutant X-chromo-
some (ratio ≥ 90:10), whereas a minor fraction (24%, 12
females out of 49) had a more moderate inactivation
(90:10 ≥ ratio ≥ 70:30) of the mutant X-chromosome,
and only three females exhibited random X-inactivation.
I
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Figure 1 ATP7A transcripts in fibroblasts from a heterozygous
female with the mutation c.1554-?_2172 +?del (Ex6_9del).
Clone 43 which is characterized by increased copper accumulation
and retention (63.4 ng
64Cu/mg protein/20 hours and 61.1%
retention) expresses only the mutant transcripts (1365 bp, missing
exon 6-9). In contrast clone 29, characterized by normal copper
uptake and retention (11.2ng
64Cu/mg protein/20 hours and 11.3%
retention) expresses only wild-type transcripts (1880 bp). In
uncloned cell populations with normal copper uptake and retention
(23.1 ng
64Cu/mg protein/20 hours and 11.3% retention) from the
same female, only normal wild-type transcripts were detected. PCR
amplification of a cDNA fragment from exon 4 to exon 10 was
performed by nested PCR with the primer-pair (5’-
caaaagcagcccaagtacctc-3’/5’-ggtggttgccagcacaatcagt-3’) followed by
the primer-pair (5’-cagaagggtcacagcaaagg-3/’5’-
ggtggttgccagcacaatcagt-3). I: index (D98-34147H), affected male
with the mutation Ex6_9del in ATP7A. C: a control sample (D98-
35541H). Pool: uncloned pool from the heterozygous female (D98-
35540H). Cl43: Clone 43. Cl29: Clone 29. The PCR products were
separated on a 2% agarose gel and visualized with ethidium
bromide.
Møller et al. Orphanet Journal of Rare Diseases 2012, 7:6
http://www.ojrd.com/content/7/1/6
Page 4 of 8These results seem to be independent of both the DNA-
source (lymphocytes, transformed lymphocytes or fibro-
blasts), family and of the type of mutation in the ATP7A
gene (Table 2 and 3).
X-inactivation patterns of normal non-carrier females
The X-inactivation patterns of 32 non-carrier females
from the same Menkes families revealed that 6 indivi-
duals had highly skewed (ratio ≥ 90:10) and 11 indivi-
duals had moderately skewed (90:10 ≥ ratio ≥ 70:30) X-
inactivation patterns. About half of the non-carriers
( 4 7 % ,1 5o f3 2 )h a da na l m o s te v e nX - i n a c t i v a t i o np a t -
tern (70:30 ≥ ratio ≥ 50:50) (Table 2 and 3).
Discussion
Affected carriers of MD are rare. In a total of 517
families we know of 9 clearly affected females. However,
we know also of mildly affected females who have not
been characterized as manifesting carriers. These mildly
affected females had pili torti, hypopigmentation of the
skin or other mild symptoms of MD. The total number
of females with any symptoms of MD is unknown.
Due to random X-inactivation, females are mosaic for
X-linked gene expression. On average, approximately
50% of the cells express genes from the paternal X-chro-
mosome and the other 50% express genes from the
Table 1 Summary of clinical, biochemical and genetic findings in manifesting carriers
Patients
Symptoms F1 (9529)
d F2 (93232) F3
(9228)
F4 (9229) F5 (91284) F6 (92209) F7 (92283) F8(92292) F9 (94228)
Mental retardation ++
5 years old,
could only
express single
words
+++
34 years old,
unable to
read, write,
talk
+++
9 years
old, no
language
+
22 years
old, mild
mental
retardation
++
10 years old,
significant
learning
difficulties
+++
2 years old,
severe
mental
retardation
+++
41 years old,
severe
mental
retardation
+
14 years
old, mild
mental
retardation
+
29 years
old, mild
mental
retardation
Motor retardation ++ +++ +++ + No + + No
Convulsions + + No No No + No
Ataxia ++ + N o +
Hypotonia ++ + + N o
Hypothermia + No + No No No
Failure to thrive ++ + N o N o
Diarrhoea - No + No No No
Dry skin ++ + + ++ + +
Skeletal Changes ++ +
Occipital horns +N o
Loose joints + + No No No +
Cutis laxa No + No No +
Abnormal hair ++ + N o ++ + +
Hypopigmentation + No + + + No +
Born, gestation
week
32
nd 38
nd 35
nd 35
nd 40
nd 38
nd 36
nd
Recurrent
infections
++ + N o
Reduced serum
Copper/
ceruloplasmin
+/+ No/No +/+ No/No No/No +/+ No/No
Increased Cu
uptake/retention
+/NA +/+ +/+ +/+ NA/NA +/+ +/+ No/+ +/+
Mutation c.1946 + 5G >
A
(IVS8 + 5G >
A)
Unknown
b c.1554-?_
1707 +?
del
(Ex6del)
c.1554-?_
2172 +?del
(Ex6_9del)
c.4123 + 5G
>A
(IVS21 + 5G >
A)
c.2179G > A
(p.G727R)
c.2383C > A
(p.R795X)
c.-22-?del
(Ex1del)
c.532G > T
(p.E178X)
X-inactivation
ratio(M:N)
a
24:76 0:100
c I.C. 80:20 51:49 4:96 0:100 I.C 100:0
Empty squares indicate that the information is not available.
aRatio denote the percentage of cells with the X-chromosome bearing the ATP7A mutation
inactivated (M): percentage of cells with the normal chromosome inactivated (N). NA; not analysed.
bThe mutation is not identified. Quantization of ATP7A mRNA
transcript revealed that the level was below the detection limit.
cWe assume that the normal allele is inactivated based on the absent of ATP7A transcript. I.C.
Inconclusive.
dF1 has two heterozygous sisters both also born prematurely, but with no symptoms of Menkes disease.
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isms for skewed X-inactivation patterns have been sug-
gested [20]: 1) Skewed X-inactivation by chance. 2) A
genetic defect in the X-inactivation process. 3) Post-
inactivation growth advantage/disadvantage for cells
with a mutation on the X-chromosome. It has been
shown that several X-linked mental retardation disor-
ders have a strong association with skewed X-chromo-
some inactivation in carrier females. The mechanism is
however unknown [21].
The observation that most unaffected carriers have an
inactivation of the mutant X-chromosome concurs with
the recent paper by Desai et al. [11], in which complete
inactivation of the mutant X-chromosome was observed
in one Menkes family with 6 heterozygous females. We
also observed skewed inactivation of the mutant X chro-
mosme in most unaffected carriers. We found highly
skewed inactivation (≥ 90:10) of the mutant X-chromo-
some in 69% of the asymptomatic carriers, and moder-
ately skewed inactivation of the mutant X-chromosome
in 24% of the carriers. Only 6% exhibited an even inacti-
vation and none of the female exhibited skewed inacti-
vation of the normal X-chromosome. Investigation of
the manifesting carriers revealed a large variation in the
observed X-inactivation pattern. Although more than
half of the affected females (57%, 4 out of 7) had skewed
inactivation of the normal X-chromosome, complete
inactivation of the mutated X-chromosome was also
observed in one female, whereas an even X-inactivation
pattern was found in another. Finally, about 19% of the
normal females without any mutation in the ATP7A
gene exhibited highly skewed X-inactivation. In conclu-
sion, skewed X-inactivation of the mutant X chromo-
some was noted in the majority of asymptomatic
carriers whereas skewed X-inactivation of the normal X-
chromosome was noted in the majority of the affected
females. Thus although a clear tendency was observed, a
number of exceptions from this tendency were observed.
X-inactivation is influenced by several factors and the
X-inactivation in DNA from blood samples, cultured
EBV transformed lymphocytes or fibroblast cultures
may not reflect the pattern in the rest of the body. In
addition, the risk of a recombination between the
ATP7A locus and the AR locus during meiosis could
lead to a faulty interpretation. The distance between the
two loci corresponds to a recombination frequency of
about 12%. Furthermore, the pattern obtained from a
cell culture might depend on the number of passages.
Long-term culture can affect the X-inactivation pattern
(own unpublished observation).
The symptoms of MD were milder in all 9 analyzed
m a n i f e s t i n gc a r r i e r st h a ni na f f e c t e dm a l e sw i t ht h e
same mutations. Whereas affected males from the same
families had the classical form of MD (except the
brother of F5 who had a slightly milder form of MD
with prolonged survival), the affected females survive
Table 2 X-inactivation pattern in affected females and family members
Family, mutation type Affected females (n = 9)
Inactivation mutant X:normal X
Unaffected carriers (n = 15)
Inactivation mutant X:normal X
Non-carriers (n = 4)
Activity of X1:X2
F1, splicing intron 8 24:76% (3426-85F) 2 people: 3 people: 95:5% (M85-3427F);
100:0% (79185F); 70:30%.(3494-85F);
98:2% (78985F)
a 70:30% (D92-5215T)
F2, unknown 0:100% (D92-6267F)
(based on Real time RT-PCR results)
b
F3, exon 6del Inconclusive (D00-43654F) 1 person: 90:10% (5974B)
F4, exon 6_9del 80:20%; 78:22% (D91-3753T; D67859F) 6 people: 98:2% (AM280F);100:0%(1161T); 1 person: 100:0% (67807F)
100:0% (67803F); 100:0% (67802F);
73:27% (44505T); 96:4% (41569B)
F5, splicing intron 21 51:49% (33744B) 1 person:78:22% (39012B)
c
F6, missense exon 10 4:96% (59135F)
F7, nonsense exon 10 0:100% (D92-5810T) 2 people:
92:8%;100:0% (D91-1195T; D95-24179F);
100:0% (D92-5613T)
F8, exon 1del Inconclusive (D92-7418F) 1 person:100:0% (D94-1503F)
d
F9, nonsense exon 3 100:0%(23508F) 2 people:
100:0% (23509F)
e;
74:26%(41882F)
DNA extracted from B: blood sample; T: transformed lymphocytes; F: cultured fibroblasts.
aSister F1-S1.
bThe mother of F2 showed also highly skewed X-inactivation pattern, but with the opposite X chromosome active.
cMother of F5.
dSister F8-S1.
eSister F9-S1.
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Five female cases of MD carrying X-autosome transloca-
tions have been described previously. Although the clini-
cal symptoms of these females are generally more severe
than the symptoms of the affected females with normal
karyotypes described here, the clinical features were, at
least also for the majority of these female patients,
milder than those of the affected boys [9,10]. Studies of
late replicating X performed in three of the five patients
with X-autosome translocations revealed that the nor-
mal X-chromosome was inactive, at least in the majority
of the analyzed cells [7,9,10].
The milder phenotypes observed in females with nor-
mal karyotypes could be attributed to higher expression
levels of the normal ATP7A gene. The degree of X-inac-
tivation of the normal X-chromosome correlated with
the degree of mental retardation. Highly skewed inacti-
vation of the normal X-chromosome was observed in
affected females with severe mental retardation (F6, F7,
and probably F2), whereas highly skewed inactivation of
the mutant X-chromosome was only observed in one
female with mild mental retardation (F9).
It has been shown that certain X-linked genes, among
them the ATP7A gene, escape X-inactivation to a cer-
tain degree [22]. This phenomenon might affect the
phenotype in both group of affected females, those with
a balanced X-autosomal translocation and those with a
normal karyotype, in which the normal X-chromosome
is inactivated. The milder phenotypes, compared to
those of affected males might be attributed to expres-
sion of normal ATP7A transcript from the inactivated
normal X-chromosome.
Conclusions
Few females are affected with MD, and their clinical
symptoms are generally milder than those of affected
Table 3 X-inactivation status of members of other families affected with MD
Family, mutation type Unaffected carriers (n = 34).
Inactivation mutant X:normal X
Non-carriers (n = 28)
Activity of X1:X2
942, 1 bp dup exon 10 2 people: 93:7% (AM45F); 91:9% (AM44F) 1 person: 46:54% (AM93F)
91207, nonsense exon 18 3 people: 99-100:1-0% (28386B; 28384B; 28356B). 1 person: 83:17% (28388B)
1 person: 54:46% (36054B) 1 person: 73:27% (36052B)
2 people: 58:42% (28389B); 58:42% (36053B)
93210, 2 bp dup exon 21 2 people: 90:10% (12499B); 98:2% (12496B)
9129, splicing intron 9 1 person: 100:0% (92-5408T) 2. people: 68:32% (91-581T); 65:35% (91-420T)
1 person: 86:14% (91-578T)
93220, splicing intron 6 2 people: 100:0%(12809F); 100:0% (12810F) 1 person: 90:10% (12746F)
1 person: 60:40% (12745F)
94252, missense exon 10 2 people: 94:6% (29620B); 100:0% (29623B) 1 person: 80:20% (29619B)
1 person: 80:20% (29617B) 2 people: 51:49% (29621B); 56:44% (29624B)
95254, missense exon 10 2 people: 98:2% (48625B); 91:8% (48627B) 1 person: 61:39% (48626B)
1 person: 74:26% (46672B)
94267, missense exon 12 2 people: 75:25% (37443B); 84:16% (37435B) 1 person: 74:26% (37437B)
2 people: 51:49%(3744B2); 52:48% (37440B)
9328, missense exon 12 1 person: 100:0% (2429T) 1 person: 78:22% (2351T)
1 person: 52:48% (2350T)
91204, exon 3_4del 2 people: 99:1% (11559F; 11761F) 1 person: 91:9% (11864B)
1 person: 73:27% (11863B)
96249, exon 8_9del 2 people: 87:13% (65547B); 83:17% (63056B) 1 person: 73:27% (67297B)
1 person: 78:22% (65646B)
9727, exon 12_15 del 1 person: 81:19% (78773B) 1 person: 86:14% (29898F)
1 person: 73:27% (32531B)
1 person: 62:38% (32532B)
91262, exon 13_17del 3 people: 99-100:1-0% (AM261F, AM264F, 51646F)
9720, missense exon 20 1 person: 92:8% (67806F) 1 person: 53:47% (67884F)
2 people: 48:52% (67808F); 37:63% (67804F)
91269, exon 13_17del 1.person:100:0% (D91-538T) 2 people:100:0% (553T); 100:0% (10340T)
1 person: 60:40% (38179F)
DNA extracted from B: blood sample; T: transformed lymphocytes; F: cultured fibroblasts.
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Page 7 of 8boys with the same mutations. Although the X-inactiva-
tion pattern correlates somewhat with presence or
absence of MD signs in female carriers, it does not suffi-
ciently explain the observed phenotypes in all of them,
as even those with a skewed inactivation of the X-chro-
mosome that harboured the mutation, might have neu-
rological symptoms. Thus, the X-inactivation pattern
alone can not be used to predict the phenotypic out-
come in female carriers.
List of abbreviations
MD: Menkes disease; MLPA: Multiplex ligation-dependent probe
amplification analysis; HUMARA: human androgen receptor.
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